Kumaran Deiva

List of Publications by Year
in descending order

71	3,654	186265 28	138484 58
papers	citations	h-index	g-index

74	74	74	3433
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Glial Fibrillary Acidic Protein Autoimmunity. Neurology, 2022, 98, .	1.1	61
2	Effect of fingolimod on health-related quality of life in paediatric patients with multiple sclerosis: results from the phase 3 PARADIGMS Study. BMJ Neurology Open, 2022, 4, e000215.	1.6	4
3	Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II. Multiple Sclerosis Journal, 2022, 28, 1562-1575.	3.0	25
4	Diagnosis and Management of Opsoclonus-Myoclonus-Ataxia Syndrome in Children. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	6.0	26
5	Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy in paediatric patients with multiple sclerosis: Results from the PARADIGMS study. Multiple Sclerosis Journal, 2021, 27, 922-932.	3.0	5
6	Imaging in Pediatric Multiple Sclerosis. Clinical Neuroradiology, 2021, 31, 61-71.	1.9	6
7	Clinical Features and Risk of Relapse in Children and Adults with Myelin Oligodendrocyte Glycoprotein Antibodyâ€“Associated Disease. Annals of Neurology, 2021, 89, 30-41.	5.3	123
8	French recommendations for the management of BehÃ§etâ€™s disease. Orphanet Journal of Rare Diseases, 2021, 16, 352.	2.7	27
9	Progressive Leukodystrophy-Like Demyelinating Syndromes with MOG-Antibodies in Children: A Rare Under-Recognized Phenotype. Neuropediatrics, 2021, 52, 337-340.	0.6	6
10	Cell-Mediated Immunity to NAGLU Transgene Following Intracerebral Gene Therapy in Children With Mucopolysaccharidosis Type IIIB Syndrome. Frontiers in Immunology, 2021, 12, 655478.	4.8	16
11	Charcotâ€“Marieâ€“Tooth disease misdiagnosed as chronic inflammatory demyelinating polyradiculoneuropathy: An international multicentric retrospective study. European Journal of Neurology, 2021, 28, 2846-2854.	3.3	22
12	Regulatory T Cells Increase After rh-MOG Stimulation in Non-Relapsing but Decrease in Relapsing MOG Antibody-Associated Disease at Onset in Children. Frontiers in Immunology, 2021, 12, 679770.	4.8	7
13	Pediatric onset multiple sclerosis: Future challenge for early diagnosis and treatment. Presse Medicale, 2021, 50, 104069.	1.9	5
14	International Consensus Recommendations for the Treatment of Pediatric NMDAR Antibody Encephalitis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	70
15	Obesity in Pediatric-Onset Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, e1044.	6.0	4
16	Intracerebral Gene Therapy in Four Children with Sanfilippo B Syndrome: 5.5-Year Follow-Up Results. Human Gene Therapy, 2021, 32, 1251-1259.	2.7	9
17	Clinical Trials for Gene Therapy in Lysosomal Diseases With CNS Involvement. Frontiers in Molecular Biosciences, 2021, 8, 624988.	3.5	21
18	Current international trends in the treatment of multiple sclerosis in childrenâ€”Impact of the COVID-19 pandemic. Multiple Sclerosis and Related Disorders, 2021, 56, 103277.	2.0	5

#	Article	IF	Citations
19	Neurological involvement in secondary hemophagocytic lymphohistiocytosis in children. European Journal of Paediatric Neurology, 2021, 34, 110-117.	1.6	3
20	Myelin-oligodendrocyte glycoprotein antibody-associated disease. Lancet Neurology, The, 2021, 20, 762-772.	10.2	261
21	Use and Safety of Immunotherapeutic Management of N-Methyl-<scp>d</scp>-Aspartate Receptor Antibody Encephalitis. JAMA Neurology, 2021, 78, 1333.	9.0	91
22	Fatigue, depression, and quality of life in children with multiple sclerosis: a comparative study with other demyelinating diseases. Developmental Medicine and Child Neurology, 2020, 62, 241-244.	2.1	15
23	E.U. paediatric MOG consortium consensus: Part 5 â€“ Treatment of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. European Journal of Paediatric Neurology, 2020, 29, 41-53.	1.6	59
24	E.U. paediatric MOG consortium consensus: Part 4 â€“ Outcome of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. European Journal of Paediatric Neurology, 2020, 29, 32-40.	1.6	29
25	E.U. paediatric MOG consortium consensus: Part 1 â€“ Classification of clinical phenotypes of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. European Journal of Paediatric Neurology, 2020, 29, 2-13.	1.6	87
26	Treatment and outcome of aquaporin-4 antibodyâ€“positive NMOSD. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	37
27	E.U. paediatric MOG consortium consensus: Part 3 â€“ Biomarkers of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. European Journal of Paediatric Neurology, 2020, 29, 22-31.	1.6	24
28	Acute Disseminated Encephalomyelitis: Current Perspectives. Children, 2020, 7, 210.	1.5	24
29	E.U. paediatric MOG consortium consensus: Part 2 â€“ Neuroimaging features of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. European Journal of Paediatric Neurology, 2020, 29, 14-21.	1.6	32
30	Dramatic efficacy of ofatumumab in refractory pediatric-onset AQP4-IgG neuromyelitis optica spectrum disorder. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	9
31	Risk factors for academic difficulties in children with myelin oligodendrocyte glycoprotein antibodyâ€associated acute demyelinating syndromes. Developmental Medicine and Child Neurology, 2020, 62, 1075-1081.	2.1	13
32	Mild Encephalitis/Encephalopathy with reversible splenial lesion syndrome: An unusual presentation of anti-GFAP astrocytopathy. European Journal of Paediatric Neurology, 2020, 26, 89-91.	1.6	21
33	Intradermal vaccination prevents anti-MOG autoimmune encephalomyelitis in macaques. EBioMedicine, 2019, 47, 492-505.	6.1	13
34	Relapsing encephalopathy with cerebellar ataxia are caused by variants involving p.Arg756 in ATP1A3. European Journal of Paediatric Neurology, 2019, 23, 448-455.	1.6	33
35	Consistent control of disease activity with fingolimod versus IFN Î²-1a in paediatric-onset multiple sclerosis: further insights from PARADIGMS. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 91, jnnp-2019-321124.	1.9	22
36	Anti-MOG autoantibodies pathogenicity in children and macaques demyelinating diseases. Journal of Neuroinflammation, 2019, 16, 244.	7.2	14

#	Article	IF	Citations
37	Cranial nerve involvement in patients with MOG antibodyâ€“associated disease. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e543.	6.0	53
38	Disease Course and Treatment Responses in Children With Relapsing Myelin Oligodendrocyte Glycoprotein Antibodyâ€“Associated Disease. JAMA Neurology, 2018, 75, 478.	9.0	306
39	Paediatric optic neuritis: factors leading to unfavourable outcome and relapses. British Journal of Ophthalmology, 2018, 102, 808-813.	3.9	13
40	Acute transverse myelitis following an opsoclonus-myoclonus syndrome: An unusual presentation. European Journal of Paediatric Neurology, 2018, 22, 878-881.	1.6	5
41	Catatonia and Autoimmune Conditions in Children and Adolescents: Should We Consider a Therapeutic Challenge?. Journal of Child and Adolescent Psychopharmacology, 2017, 27, 167-176.	1.3	15
42	Intracerebral gene therapy in children with mucopolysaccharidosis type IIIB syndrome: an uncontrolled phase 1/2 clinical trial. Lancet Neurology, The, 2017, 16, 712-720.	10.2	149
43	MOG antibody-related disorders: common features and uncommon presentations. Journal of Neurology, 2017, 264, 1945-1955.	3.6	119
44	Neurological outcome of patients with cryopyrin-associated periodic syndrome (CAPS). Orphanet Journal of Rare Diseases, 2017, 12, 33.	2.7	28
45	Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients. Journal of the Neurological Sciences, 2017, 381, 240-244.	0.6	29
46	Pediatric transverse myelitis. Neurology, 2016, 87, S46-52.	1.1	92
47	Vessel Wall Contrast Enhancement on Magnetic Resonance Imaging May Be Suggestive for Future Development of Further Arterial Changes. Canadian Journal of Neurological Sciences, 2016, 43, 728-730.	0.5	1
48	Rituximab monitoring and redosing in pediatric neuromyelitis optica spectrum disorder. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e188.	6.0	60
49	Early-onset stroke with moyamoya-like syndrome and extraneurological signs: a first reported paediatric series. European Radiology, 2016, 26, 2853-2862.	4.5	7
50	Treatment and outcome of children and adolescents with N-methyl-d-aspartate receptor encephalitis. Journal of Neurology, 2015, 262, 1859-1866.	3.6	105
51	Acute idiopathic transverse myelitis in children. Neurology, 2015, 84, 341-349.	1.1	56
52	Myelin oligodendrocyte glycoprotein antibodies are associated with a non-MS course in children. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e81.	6.0	205
53	Extracranial vertebral artery dissection in children: natural history and management. Neuroradiology, 2015, 57, 729-738.	2.2	12
54	Increased interleukin-6 correlates with myelin oligodendrocyte glycoprotein antibodies in pediatric monophasic demyelinating diseases and multiple sclerosis. Journal of Neuroimmunology, 2015, 289, 1-7.	2.3	40

#	Article	IF	Citations
55	Promoting physical activity to control multiple sclerosis from childhood. Neurology, 2015, 85, 1644-1645.	1.1	5
56	Intrathecal treatment of antiâ€Nâ€Methylâ€<scp>d</scp>â€aspartate receptor encephalitis in children. Developmental Medicine and Child Neurology, 2015, 57, 95-99.	2.1	48
57	Sudden and isolated Broca's aphasia: A new clinical phenotype of anti NMDA receptor antibodies encephalitis in children. European Journal of Paediatric Neurology, 2014, 18, 790-792.	1.6	14
58	Intracerebral Administration of Adeno-Associated Viral Vector Serotype rh.10 Carrying Human SGSH and SUMF1 cDNAs in Children with Mucopolysaccharidosis Type IIIA Disease: Results of a Phase I/II Trial. Human Gene Therapy, 2014, 25, 506-516.	2.7	213
59	Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease. Neurology, 2014, 83, 142-150.	1.1	275
60	Nâ€methylâ€Dâ€aspartate receptor antibodies in postâ€“herpes simplex virus encephalitis neurological relapse. Movement Disorders, 2014, 29, 90-96.	3.9	192
61	Creatine and guanidinoacetate reference values in a French population. Molecular Genetics and Metabolism, 2013, 110, 263-267.	1.1	32
62	Fulminant toxic shock syndrome following rituximab therapy in an 11-year-old boy. Journal of Neurology, 2013, 260, 2892-2893.	3.6	2
63	Hashimoto's encephalopathy: Identification and long-term outcome in children. European Journal of Paediatric Neurology, 2013, 17, 280-287.	1.6	40
64	Autoimmune limbic encephalopathy and anti-Hu antibodies in children without cancer. Neurology, 2013, 80, 2226-2232.	1.1	68
65	CNS involvement at the onset of primary hemophagocytic lymphohistiocytosis. Neurology, 2012, 78, 1150-1156.	1.1	115
66	Screening for primary creatine deficiencies in French patients with unexplained neurological symptoms. Orphanet Journal of Rare Diseases, 2012, 7, 96.	2.7	33
67	Febrile Brain Stroke and Tuberculous Meningitis: Persisting Threat in Non-Endemic Countries. Neuropediatrics, 2010, 41, 273-275.	0.6	1
68	Effects of SDF-1Î± and gp120IIIB on apoptotic pathways in SK-N-SH neuroblastoma cells. Neuroscience Letters, 2006, 399, 115-120.	2.1	14
69	CCR5-, DC-SIGN-Dependent Endocytosis and Delayed Reverse Transcription after Human Immunodeficiency Virus Type 1 Infection in Human Astrocytes. AIDS Research and Human Retroviruses, 2006, 22, 1152-1161.	1.1	22
70	Fractalkine reduces N-methyl-d-aspartate-induced calcium flux and apoptosis in human neurons through extracellular signal-regulated kinase activation. European Journal of Neuroscience, 2004, 20, 3222-3232.	2.6	55
71	Early and aggressive treatment may modify anti Hu associated encephalitis prognosis. Neuropediatrics, 0, , .	0.6	0